Exact Sciences closed at $78.75 in the latest trading session, marking a +0.85% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.84%. Elsewhere, the Dow gained 1.06%, while the tech-heavy Nasdaq added 0.1%.
Coming into today, shares of the molecular diagnostics company had gained 4.93% in the past month. In that same time, the Medical sector lost 2.97%, while the S&P 500 lost 4.03%.
Investors will be hoping for strength from Exact Sciences as it approaches its next earnings release. The company is expected to report EPS of -$0.91, down 911.11% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $454.75 million, down 2.49% from the year-ago period.
It is also important to note the recent changes to analyst estimates for Exact Sciences. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 1.44% lower. Exact Sciences is holding a Zacks Rank of #4 (Sell) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 144, putting it in the bottom 44% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow EXAS in the coming trading sessions, be sure to utilize Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Exact Sciences (EXAS) Outpaces Stock Market Gains: What You Should Know
Exact Sciences closed at $78.75 in the latest trading session, marking a +0.85% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.84%. Elsewhere, the Dow gained 1.06%, while the tech-heavy Nasdaq added 0.1%.
Coming into today, shares of the molecular diagnostics company had gained 4.93% in the past month. In that same time, the Medical sector lost 2.97%, while the S&P 500 lost 4.03%.
Investors will be hoping for strength from Exact Sciences as it approaches its next earnings release. The company is expected to report EPS of -$0.91, down 911.11% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $454.75 million, down 2.49% from the year-ago period.
It is also important to note the recent changes to analyst estimates for Exact Sciences. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 1.44% lower. Exact Sciences is holding a Zacks Rank of #4 (Sell) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 144, putting it in the bottom 44% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow EXAS in the coming trading sessions, be sure to utilize Zacks.com.